Primary target audience for this education are primary care physicians. The secondary target audience is primary care nurse practitioners and physician associates/physician assistants.
The goal of this program is to improve primary care provider knowledge, competence (application of knowledge), and demonstrated improvement in clinical performance to optimize treatment for patients with obesity.
Upon completion of this activity, participants should be able to:
Develop strategies to overcome biases and barriers associated with the chronic management of obesity
Compare the latest efficacy and safety data of current and emerging antiobesity medications
Incorporate guideline recommendations, the latest clinical evidence, and patient-specific factors to select antiobesity medications for long-term management among appropriate patients
Apply strategies to improve the likelihood of long-term weight loss based on an assessment of treatment response, patient preferences, and adherence
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Donna H. Ryan, MD
Pennington Biomedical Research Center
New Orleans, Louisiana
Donna Ryan, MD: advisor: Altimmune, Amgen, Biohaven, Boeringer Ingelheim, Calibrate, Carmot, Epitomee, Gila Therapeutics, Lilly, Novo Nordisk, Scientific Intake, Structure Tx, Xeno, YSOPIA, Zealand; speaker: IFA Celtic, Novo Nordisk, Lilly; individual publicly traded stock/stock options: Epitomee, Calibrate, Ro, Scientific Intake, Xeno; clinical trial: Novo Nordisk; data safety monitoring board: IQVIA (Rhythm), Lilly.
Christopher D. Still, DO, FACN, FACP, FTOS
Professor of Medicine
Department of Clinical Sciences
Geisinger Commonwealth School of Medicine
Center for Nutrition & Weight Management
Geisinger Obesity Institute
Christopher D. Still, DO, FACN, FACP: consultant/advisor/speaker: Novo Nordisk, Twenty30 Heath; researcher: Ethicon Endosurgery.
Robert Kushner, MD, MS
Departments of Medicine and Medical Education
Feinberg School of Medicine
Center for Lifestyle Medicine
Robert Kushner, MD, MS, FACP, DABOM: consultant/advisor/speaker: Lilly, Novo Nordisk, Pfizer, WW; researcher: Epitomee.
The planners and content peer reviewers from Clinical Care Options, LLC and RealCME do not have any relevant financial relationships to disclose, except Amy Butts, PA-C, as noted below.
Amy Butts, PA-C: consultant: Bayer, Novo Nordisk, Provention Bio, Xeris.
Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 05, 2023, through June 04, 2024:
1. Login or Sign Up for an account by clicking at the top of this page
2. Read the target audience, learning objectives, and faculty disclosures
3. View and study the content in its entirety
4. Submit answers to the post-test questions and evaluation questions online
You must receive a test score of 65% or better and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.
Physician Assistant/Physician Associate Continuing Medical Education
Clinical Care Options has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until June 04, 2024. PAs should only claim credit commensurate with the extent of their participation.